NanoVation Therapeutics

What NanoVation Therapeutics does

NanoVation Therapeutics is a private Canadian biotechnology company headquartered in Vancouver, BC, founded in 2019 by a multi-institutional team of LNP scientists from the University of British Columbia, the Medical College of Wisconsin, and other institutions. The company develops next-generation lipid nanoparticle (LNP) delivery technologies designed to overcome the principal bottleneck in genetic medicine: safe and efficient delivery of nucleic acids to tissues beyond the liver. Its flagship long-circulating LNP (lcLNP™) platform demonstrates up to 18-hour circulation half-life in non-human primates (versus less than one hour for conventional LNPs) and has shown functional delivery to bone marrow, solid tumors, immune compartments, and skin.

The technology stack is anchored by the proprietary lcLNP platform and the broader NTx Toolbox, a one-stop-shop intellectual property portfolio that spans novel ionizable lipid libraries synthesized via low-cost bucket chemistry, proprietary mRNA modifications and caps, LNP compositions, and surface modifications including PEGless formulations. Supporting infrastructure includes the GENErator™ encapsulation facility in Harwell, UK, and a European office in Berlin, complementing the UBC-campus headquarters. Named scientific leadership includes Pieter Cullis (Board Chair), Dominik Witzigmann (President), and Jayesh Kulkarni (CSO), supported by advisors and board members with track records at companies that delivered Onpattro and Comirnaty.

NanoVation operates a B2B platform business model, monetizing through collaborative co-development arrangements, licensing, milestone payments, and tiered royalties with pharmaceutical and biotechnology partners. Customers to date include Novo Nordisk (multi-target genetic medicine partnership with up to US$600 million in upfront and milestone potential), Baseimmune (preclinical mRNA vaccines), and ME Therapeutics (myeloid-cell cancer therapeutics). The company also benefits from non-dilutive government grant funding through programs such as Innovate BC's Ignite award.

Name

NanoVation Therapeutics

Legal name

NanoVation Therapeutics Inc.

Website

https://nanovationtx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

NanoVation Therapeutics is a Vancouver-based private biotechnology company that develops proprietary long-circulating lipid nanoparticle (lcLNP™) technology for nucleic acid delivery beyond the liver. It serves pharmaceutical and biotechnology partners through collaborative co-development, licensing, and milestone-based agreements.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

Keywords

• Lipid nanoparticle delivery
• Nucleic acid therapeutics
• Genetic medicine platforms
• MRNA delivery systems
• Extrahepatic drug delivery

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Partnership and Licensing Revenue: Research funding and milestone payments from pharmaceutical partners. Eligibility for up to US$600 million in upfront cash and potential milestone payments plus tiered royalties on future product sales from Novo Nordisk partnership. Multi-year collaborative arrangements with upfront payments, development milestones, and commercial royalties.
2. Government Grants: Innovation BC Ignite program funding awards for research and development projects, such as the $300,000 award for mRNA stability and production enhancement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

NanoVation Therapeutics develops and provides lipid nanoparticle (LNP) delivery technologies for nucleic acid-based therapeutics. Its flagship offering is the long-circulating LNP (lcLNP) platform, which enables functional delivery of mRNA, siRNA, DNA, and gene editing constructs to tissues beyond the liver (bone marrow, tumors, immune compartments, skin). The company offers customized LNP design and a co-development partnership model for pharmaceutical and biotechnology clients developing genetic medicines.

Product overview

NanoVation Therapeutics is a platform company developing next-generation lipid nanoparticle (LNP) technologies for nucleic acid delivery. The company's core offering consists of its proprietary long-circulating LNP (lcLNP™) platform as the flagship technology, complemented by the NTx Toolbox which provides a comprehensive IP portfolio covering ionizable lipid libraries, LNP compositions, surface modifications, and mRNA modifications. The platform enables customized delivery solutions for various tissues (beyond the liver), payloads (mRNA, siRNA, DNA, gene editing constructs), and administration routes. The company also offers HepLNP for liver-targeted delivery and operates the GENErator™ facility for partner programs.

Differentiator

Problem solved

Functional benefit

Products and services

• lcLNP™ (Long-Circulating LNP) Platform

Quantifiable outcome

• Up to 18h circulation half-life in NHP (vs <1h for conventional LNPs)
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and secondary.

• Novo NordiskcoreStrategic or Co-development Partner · 18 September 2024Multi-year partnership to develop genetic medicines targeting cardiometabolic and rare diseases. NanoVation will receive research funding and is eligible to receive up to approximately US$600 million in upfront cash and potential milestone payments, plus tiered royalties on future product sales. Partnership focuses on two lead programs for base-editing therapies targeting rare genetic diseases and up to five additional future targets, utilizing NanoVation's lcLNP technology for extrahepatic delivery.
• BaseimmunecoreStrategic or Co-development Partner · 14 September 2022Preclinical partnership program to develop more effective vaccines against COVID, malaria, and African swine fever. Baseimmune creates informatics-empowered universal antigens and NanoVation provides customized LNP formulations for mRNA delivery. Testing conducted in preclinical models by Baseimmune. Baseimmune in London will create antigen-encoded mRNA and NanoVation's GENErator facility in Harwell, UK will encapsulate mRNA in tailor-made LNPs.
• ME TherapeuticssecondaryStrategic or Co-development PartnerPartnership to target myeloid cells with precision for cancer therapeutics using NanoVation's lcLNP platform. ME Therapeutics describes the collaboration as transformative for entering the field of therapeutic mRNA development.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Acuitas Therapeutics: Vancouver-based LNP delivery technology company that developed the LNP system for Pfizer-BioNTech's Comirnaty COVID-19 vaccine. Direct competitor to NanoVation in ionizable lipid LNP technology for nucleic acid delivery, with established enterprise pharma partnerships.
• Genevant Sciences: LNP and ligand-based delivery platform for RNA therapeutics with multiple pharma partnerships. Competes directly with NanoVation in developing next-generation LNPs for nucleic acid payloads, particularly for extrahepatic delivery.

Emerging players

• Replicate Bioscience: Clinical-stage RNA therapeutics company with proprietary self-replicating RNA platform. Comparable as an emerging player developing novel RNA delivery approaches for cancer and infectious disease applications.
• Strand Therapeutics: Developer of mRNA therapeutics with programmable, self-replicating RNA technology for cancer and other diseases. Comparable as an emerging genetic medicines company working on novel delivery and RNA design for extrahepatic indications.
• Etherna Immunotherapies: Belgium-based developer of mRNA immunotherapies using proprietary LNP and lipopolyplex delivery technologies. Comparable in combining novel delivery technology with therapeutic partnerships, though more vertically integrated than NanoVation.

Broad incumbents

• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LNP delivery technology and self-amplifying RNA platforms. Comparable in its focus on combining novel nucleic acid payloads with custom LNPs, though it owns clinical assets rather than partnering only at the platform level.
• BioNTech: Global mRNA therapeutics leader with extensive internal LNP and lipid chemistry capabilities acquired through its University of Pennsylvania and Acuitas-adjacent work. Comparable in target market (pharma/biotech needing LNP delivery) but operates at vastly larger scale with internal pipeline.
• CureVac: Clinical-stage mRNA therapeutics company with proprietary lipid carriers and RNA optimization technology. Comparable as a developer of novel LNPs and mRNA modifications for therapeutic applications, though it operates its own clinical pipeline.
• Moderna: Commercial-stage mRNA company with proprietary LNP delivery technology used in approved COVID-19 and RSV vaccines. Competes in the broader nucleic acid delivery market and has internal R&D programs targeting extrahepatic delivery.
• Precision NanoSystems (Cytiva): Provides LNP formulation technologies, microfluidic manufacturing equipment, and CDMO services for nanomedicine development. Comparable as a one-stop LNP platform and services provider for pharma and biotech partners developing nucleic acid therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCTuOj16howP3dfz41JOzodg
• LinkedInlinkedin.com/company/nanovationtx

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoVation Therapeutics